deferiprone has been researched along with Anemia in 16 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions." | 8.83 | Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006) |
| "Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions." | 4.83 | Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006) |
| "Deferiprone is the most widely studied oral iron chelator and, at present, the only one shown to be effective in achieving negative iron balance in long-term clinical trials for chronic iron overload." | 4.79 | Oral iron chelation with deferiprone. ( Diav-Citrin, O; Koren, G, 1997) |
| "Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints." | 2.44 | Chelation therapy for iron overload. ( Barton, JC, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Modell, B | 2 |
| Khan, M | 1 |
| Darlison, M | 1 |
| Westwood, MA | 1 |
| Ingram, D | 1 |
| Pennell, DJ | 1 |
| McLeod, C | 1 |
| Fleeman, N | 1 |
| Kirkham, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Chu, P | 1 |
| Dickson, R | 1 |
| Dundar, Y | 1 |
| Greenhalgh, J | 1 |
| Olujohungbe, A | 1 |
| Telfer, P | 1 |
| Walley, T | 1 |
| Fernandes, JL | 1 |
| Fabron, A | 1 |
| Verissimo, M | 1 |
| Porter, JB | 1 |
| Merson, L | 1 |
| Olivier, N | 1 |
| Lucas, GN | 1 |
| Perera, BJ | 1 |
| Fonseka, EA | 1 |
| De Silva, DD | 1 |
| Fernandopulle, M | 1 |
| Karunatilaka, DH | 1 |
| Weerasinghe, I | 1 |
| Kontoghiorghes, GJ | 4 |
| Barton, JC | 1 |
| al-Refaie, FN | 1 |
| Hoffbrand, AV | 3 |
| Diav-Citrin, O | 1 |
| Koren, G | 1 |
| Alter, BP | 1 |
| Bartlett, AN | 2 |
| Goddard, JG | 1 |
| Sheppard, L | 1 |
| Barr, J | 1 |
| Nortey, P | 1 |
| Vreugdenhil, G | 2 |
| Swaak, AJ | 2 |
| de Jeu-Jaspers, C | 1 |
| van Eijk, HG | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Trial of Oral Nifedipine for the Treatment of Iron Overload[NCT00712738] | Phase 1 | 6 participants (Actual) | Interventional | 2008-06-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for deferiprone and Anemia
| Article | Year |
|---|---|
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferipro | 2009 |
Orally active iron chelators.
Topics: Administration, Oral; Anemia; Blood Transfusion; Deferiprone; Humans; Iron Chelating Agents; Iron Ov | 2002 |
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Topics: Anemia; Chelation Therapy; Chronic Disease; Combined Modality Therapy; Deferiprone; Humans; Iron; Ir | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferipron | 2007 |
Oral iron-chelating therapy: the L1 experience.
Topics: Administration, Oral; Anemia; Animals; beta-Thalassemia; Chelation Therapy; Deferiprone; Humans; Iro | 1994 |
Oral iron chelation with deferiprone.
Topics: Acute Disease; Administration, Oral; Anemia; Chelation Therapy; Child; Deferiprone; Humans; Iron Ove | 1997 |
4 trials available for deferiprone and Anemia
| Article | Year |
|---|---|
Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254.
Topics: Anemia; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload | 2023 |
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
Topics: Anemia; Blood Transfusion; Deferiprone; Ferritins; Half-Life; Humans; Iron; Iron Chelating Agents; M | 1990 |
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations.
Topics: Adolescent; Adult; Aged; Anemia; Blood Transfusion; Deferiprone; Female; Humans; Iron; Iron Chelatin | 1990 |
Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients.
Topics: Administration, Oral; Anemia; Arthritis, Rheumatoid; Deferiprone; Humans; Iron Chelating Agents; Pyr | 1989 |
6 other studies available for deferiprone and Anemia
| Article | Year |
|---|---|
Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.
Topics: Adolescent; Adult; Anemia; beta-Thalassemia; Bone Marrow Transplantation; Cardiomyopathies; Cause of | 2008 |
Early cardiac iron overload in children with transfusion-dependent anemias.
Topics: Adolescent; Anemia; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Deferiprone; Defe | 2009 |
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.
Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Ove | 2009 |
Experience with the oral iron chelator deferiprone in transfusion-dependent children.
Topics: Administration, Oral; Adolescent; Anemia; Blood Transfusion; Child; Child, Preschool; Deferiprone; F | 2002 |
Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelation.
Topics: Administration, Oral; Agranulocytosis; Anemia; Deferiprone; Humans; Iron Chelating Agents; Leukocyte | 1990 |
Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis.
Topics: Anemia; Arthritis, Rheumatoid; Deferiprone; Humans; Iron Chelating Agents; Pyridones | 1990 |